keyword
MENU ▼
Read by QxMD icon Read
search

Hairy cell leukaemia

keyword
https://www.readbyqxmd.com/read/27808110/structural-characterisation-of-high-affinity-siglec-2-cd22-ligands-in-complex-with-whole-burkitt-s-lymphoma-bl-daudi-cells-by-nmr-spectroscopy
#1
Paul D Madge, Andrea Maggioni, Mauro Pascolutti, Moein Amin, Mario Waespy, Bernadette Bellette, Robin J Thomson, Sørge Kelm, Mark von Itzstein, Thomas Haselhorst
Siglec-2 undergoes constitutive endocytosis and is a drug target for autoimmune diseases and B cell-derived malignancies, including hairy cell leukaemia, marginal zone lymphoma, chronic lymphocytic leukaemia and non-Hodgkin's lymphoma (NHL). An alternative to current antibody-based therapies is the use of liposomal nanoparticles loaded with cytotoxic drugs and decorated with Siglec-2 ligands. We have recently designed the first Siglec-2 ligands (9-biphenylcarboxamido-4-meta-nitrophenyl-carboxamido-Neu5Acα2Me, 9-BPC-4-mNPC-Neu5Acα2Me) with simultaneous modifications at C-4 and C-9 position...
November 3, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27391097/excellent-outcome-of-hairy-cell-leukaemia-with-extensive-mesenteric-infiltration-following-cladribine-therapy
#2
Luis Miguel Juárez Salcedo, Jose Sandoval-Sus, Ling Zhang, Donald Klippenstein, Julio C Chavez
No abstract text is available yet for this article.
September 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27351754/treatment-outcomes-and-secondary-cancer-incidence-in-young-patients-with-hairy-cell-leukaemia
#3
Bartlomiej M Getta, Kaitlin M Woo, Sean Devlin, Jae H Park, Omar Abdel-Wahab, Alan Saven, Kanti Rai, Martin S Tallman
Repeated therapy of hairy cell leukaemia (HCL) with treatments that have potential long-term toxicities has raised concerns regarding increased risk for younger patients. We compared clinical outcomes and disease complications in 63 patients with HCL aged ≤40 years at diagnosis with 268 patients >40 years treated at Memorial Sloan Kettering Cancer Center. The rate of complete remission following initial therapy was 87% and 83% (P = 0·71) and estimated 10-year overall survival was 100% and 82% (P = 0·25) in younger and older patients, respectively...
November 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27301277/long-term-durable-remission-by-cladribine-followed-by-rituximab-in-patients-with-hairy-cell-leukaemia-update-of-a-phase-ii-trial
#4
Dai Chihara, Hagop Kantarjian, Susan O'Brien, Jeffrey Jorgensen, Sherry Pierce, Stefan Faderl, Alessandra Ferrajoli, Rebecca Poku, Preetesh Jain, Phillip Thompson, Mark Brandt, Rajyalakshmi Luthra, Jan Burger, Michael Keating, Farhad Ravandi
Nucleoside analogues are highly active in patients with hairy cell leukaemia (HCL); however, patients continue to relapse. This phase II study evaluated the efficacy and safety of cladribine followed by rituximab in patients with untreated HCL (N = 59), relapsed HCL (N = 14) and HCL variant (HCLv, N = 7). Cladribine 5·6 mg/m(2) was given intravenously (IV) daily for 5 d and was followed approximately 1 month later with rituximab 375 mg/m(2) IV weekly for 8 weeks. Complete response rate in patients with untreated HCL, relapsed HCL and HCLv was 100%, 100% and 86%, respectively...
September 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27066918/hes1-in-immunity-and-cancer
#5
Aradhana Rani, Roseanna Greenlaw, Richard A Smith, Christine Galustian
Hairy and enhancer of split homolog-1 (HES1) is a part of an extensive family of basic helix-loop-helix (bHLH) proteins and plays a crucial role in the control and regulation of cell cycle, proliferation, cell differentiation, survival and apoptosis in neuronal, endocrine, T-lymphocyte progenitors as well as various cancers. HES1 is a transcription factor which is regulated by the NOTCH, Hedgehog and Wnt signalling pathways. Aberrant expression of these pathways is a common feature of cancerous cells. There appears to be a fine and complicated crosstalk at the molecular level between the various signalling pathways and HES1, which contributes to its effects on the immune response and cancers such as leukaemia...
August 2016: Cytokine & Growth Factor Reviews
https://www.readbyqxmd.com/read/26893254/potential-role-of-akt-mtor-signalling-proteins-in-hairy-cell-leukaemia-association-with-braf-erk-activation-and-clinical-outcome
#6
Eleftheria Lakiotaki, Georgia Levidou, Maria K Angelopoulou, Christos Adamopoulos, Gerassimos Pangalis, George Rassidakis, Theodoros Vassilakopoulos, Gabriella Gainaru, Pagona Flevari, Sotirios Sachanas, Angelica A Saetta, Athanasia Sepsa, Maria Moschogiannis, Christina Kalpadakis, Nikolaos Tsesmetzis, Vassilios Milionis, Ilenia Chatziandreou, Irene Thymara, Panayiotis Panayiotidis, Maria Dimopoulou, Eleni Plata, Konstantinos Konstantopoulos, Efstratios Patsouris, Christina Piperi, Penelope Korkolopoulou
The potential role of AKT/mTOR signalling proteins and its association with the Raf-MEK-ERK pathway was investigated in hairy cell leukaemia (HCL). BRAFV600E expression and activated forms of AKT, mTOR, ERK1/2, p70S6k and 4E-BP1 were immunohistochemically assessed in 77 BM biopsies of HCL patients and correlated with clinicopathological and BM microvascular characteristics, as well as with c-Caspase-3 levels in hairy cells. Additionally, we tested rapamycin treatment response of BONNA-12 wild-type cells or transfected with BRAFV600E...
2016: Scientific Reports
https://www.readbyqxmd.com/read/26871591/exome-sequencing-in-classic-hairy-cell-leukaemia-reveals-widespread-variation-in-acquired-somatic-mutations-between-individual-tumours-apart-from-the-signature-braf-v-600-e-lesion
#7
Nicola J Weston-Bell, Will Tapper, Jane Gibson, Dean Bryant, Yurany Moreno, Melford John, Sarah Ennis, Hanneke C Kluin-Nelemans, Andrew R Collins, Surinder S Sahota
In classic Hairy cell leukaemia (HCLc), a single case has thus far been interrogated by whole exome sequencing (WES) in a treatment naive patient, in which BRAF V(600)E was identified as an acquired somatic mutation and confirmed as occurring near-universally in this form of disease by conventional PCR-based cohort screens. It left open however the question whether other genome-wide mutations may also commonly occur at high frequency in presentation HCLc disease. To address this, we have carried out WES of 5 such typical HCLc cases, using highly purified splenic tumour cells paired with autologous T cells for germline...
2016: PloS One
https://www.readbyqxmd.com/read/26614904/hairy-cell-leukaemia-variant-disease-features-and-treatment
#8
REVIEW
Estella Matutes, Alejandra Martínez-Trillos, Elias Campo
Hairy cell leukaemia-variant (HCL-V) is a rare B-cell malignancy that affects elderly males and manifests with splenomegaly, lymphocytosis and cytopenias without monocytopenia. The neoplastic cells have morphological features of prolymphocytes and hairy cells. The immunophenotype is that of a clonal B-cell CD11c and CD103 positive but, unlike classical HCL, CD25, CD123 and CD200 negative. The spleen histology is similar to classical HCL and the pattern of bone marrow infiltration is interstitial and/or intrasinusoidal...
December 2015: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/26614900/long-term-follow-up-after-purine-analogue-therapy-in-hairy-cell-leukaemia
#9
REVIEW
Monica Else, Claire E Dearden, Daniel Catovsky
Since 2006 when we last reviewed the literature concerning the use of purine analogues in hairy cell leukaemia (HCL), results from several new and updated series have been published. Here we examine these reports and consider their implications for patient management. The two purine analogues pentostatin and cladribine remain the first-line treatments of choice for all patients with HCL. Although they have not been compared in randomised trials, they appear to be equally effective. A complete response is important for the long-term outcome and we look at how best this can be achieved...
December 2015: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/26614898/bone-marrow-and-splenic-histology-in-hairy-cell-leukaemia
#10
REVIEW
Andrew Wotherspoon, Ayoma Attygalle, Larissa Sena Teixeira Mendes
Hairy cell leukaemia is a rare chronic neoplastic B-cell lymphoproliferation that characteristically involves blood, bone marrow and spleen with liver, lymph node and skin less commonly involved. Histologically, the cells have a characteristic appearance with pale/clear cytoplasm and round or reniform nuclei. In the spleen, the infiltrate involves the red pulp and is frequently associated with areas of haemorrhage (blood lakes). The cells stain for B-cell related antigens as well as with antibodies against tartrate-resistant acid phosphatase, DBA44 (CD72), CD11c, CD25, CD103, CD123, cyclin D1 and annexin A1...
December 2015: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/26614895/epidemiology-and-environmental-risk-in-hairy-cell-leukemia
#11
REVIEW
Tamar Tadmor, Aaron Polliack
Hairy cell leukaemia (HCL) is an orphan subtype of leukaemia which constitutes less than 2% of all leukaemia's, with an incidence of less than 1 per 100,000 persons per annum. Median age at presentation is 55 years and it is 3-4 times more frequent in males. It is also more frequently encountered in whites and less in Asians, Africans and Arabs. The epidemiologic data are multi-factorial and influenced by ethnicity and geographical factors. Other reported associations relate to some environmental exposures and possible occupational factors...
December 2015: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/26609034/haematological-profile-of-21-patients-with-hairy-cell-leukaemia-in-a-tertiary-care-centre-of-north-india
#12
Arvind Kumar Gupta, Man Updesh Singh Sachdeva, Jasmina Ahluwalia, Reena Das, Shano Naseem, Prashant Sharma, Narender Kumar, Pankaj Malhotra, Neelam Varma, Subhash Varma
BACKGROUND & OBJECTIVES: Hairy cell leukaemia (HCL) is a B cell neoplasm which constitutes around 2 per cent of all the lymphoid leukaemias. It has a characteristic morphology and immunophenotypic profile. It is important to distinguish HCL from other B cell lymphoproliferative disorders due to availability of different chemotherapeutic agents. This study presents clinical, haematological and immunophenotypic profile of patients with HCL seen over a period of four years in a tertiary care hospital in north India...
October 2015: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/26403440/an-unusual-indication-for-splenectomy-in-hairy-cell-leukaemia-a-report-of-three-cases-with-persistent-splenomegaly-after-chemoimmunotherapy
#13
Nadav Sarid, Humayun N Ahmad, Andrew Wotherspoon, Claire E Dearden, Monica Else, Daniel Catovsky
We describe three cases of relapsed hairy cell leukaemia (HCL) treated with pentostatin plus rituximab. All three achieved bone marrow complete remission but had persistent splenomegaly and hypersplenism. Because of the clinical uncertainty of its significance, they were all splenectomized. The spleen histology showed no evidence of HCL, but a five-fold thickening of the splenic capsule and areas of fibrosis in the red pulp. This process may have contributed to the lack of elasticity and caused the persistent splenomegaly...
December 2015: British Journal of Haematology
https://www.readbyqxmd.com/read/26387749/vemurafenib-for-relapsed-or-refractory-hairy-cell-leukaemia
#14
Holly Baker
No abstract text is available yet for this article.
October 2015: Lancet Oncology
https://www.readbyqxmd.com/read/26269205/hairy-cell-leukaemia-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up
#15
T Robak, E Matutes, D Catovsky, P L Zinzani, C Buske
No abstract text is available yet for this article.
September 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/26115047/melanoma-and-non-melanoma-skin-cancers-in-hairy-cell-leukaemia-a-surveillance-epidemiology-and-end-results-population-analysis-and-the-30-year-experience-at-memorial-sloan-kettering-cancer-center
#16
Justin M Watts, Ashwin Kishtagari, Meier Hsu, Mario E Lacouture, Michael A Postow, Jae H Park, Eytan M Stein, Julie Teruya-Feldstein, Omar Abdel-Wahab, Sean M Devlin, Martin S Tallman
Few studies have examined melanoma and non-melanoma skin cancer (NMSC) incidence rates after a diagnosis of hairy cell leukaemia (HCL). We assessed 267 HCL patients treated at Memorial Sloan Kettering Cancer Center (MSKCC) and Surveillance, Epidemiology and End Results (SEER) data for melanoma and NMSC incidence rates after HCL. Incidence data from MSKCC patients demonstrated a 10-year combined melanoma and NMSC skin cancer rate of 11·3%, melanoma 4·4% and NMSC 6·9%. Molecular analysis of skin cancers from MSKCC patients revealed activating RAS mutations in 3/9 patients, including one patient with melanoma...
October 2015: British Journal of Haematology
https://www.readbyqxmd.com/read/26049757/hairy-cell-leukemia-update-and-current-therapeutic-approach
#17
REVIEW
Latif Salam, Omar Abdel-Wahab
PURPOSE OF REVIEW: In this review, we discuss the pathogenesis and standard therapeutic approach to hairy cell leukaemia (HCL) as well as newer targeted therapies under investigation showing promising end-points in treating HCL. RECENT FINDINGS: HCL is an indolent B-cell leukaemia. Historically, HCL patients have achieved excellent response to purine nucleoside analogues and single purine analogue treatment with pentostatin or cladribine is currently the standard of care for initial treatment...
July 2015: Current Opinion in Hematology
https://www.readbyqxmd.com/read/25938346/braf-mutation-detection-in-hairy-cell-leukaemia-from-archival-haematolymphoid-specimens
#18
Carla Thomas, Benhur Amanuel, Jill Finlayson, Fabienne Grieu-Iacopetta, Dominic V Spagnolo, Wendy N Erber
Hairy cell leukaemia (HCL) is a rare, indolent chronic B-cell leukaemia accounting for approximately 2% of all adult leukaemias. The recent association of the BRAF p.Val600Glu (V600E) mutation in HCL makes it a valuable molecular diagnostic marker. We compared the ability of Sanger sequencing, fluorescent single-strand conformational polymorphism (F-SSCP) and high resolution melting (HRM) analysis to detect BRAF mutations in 20 cases of HCL consisting of four archival Romanowsky stained air-dried peripheral blood and bone marrow aspirate smears, 12 mercury fixed decalcified bone marrow trephine biopsies, three formalin fixed, paraffin embedded (FFPE) splenectomy samples and one fresh peripheral blood sample...
June 2015: Pathology
https://www.readbyqxmd.com/read/25673595/v-raf-murine-sarcoma-viral-oncogene-homolog-b-braf-mutations-in-hairy-cell-leukaemia
#19
Neeraj Arora, Sheila Nair, Rekha Pai, Sukesh Nair, Rayaz Ahmed, Aby Abraham, Auro Viswabandya, Biju George, Poonkuzhali Balasubramanian, Alok Srivastava, Vikram Mathews
INTRODUCTION: Hairy cell leukemia (HCL) is a B-cell non-Hodgkin lymphoma with distinct clinical, morphological and immunophenotypic features; however, there are many other B-cell lymphomas, which closely mimic HCL. Accurate diagnosis of HCL is important as treatment with 2-chloro-2'-deoxyadenosine (cladribine) is associated with >80% chance of complete cure. The recent description of BRAF p.V600E mutations in almost all HCL cases in various studies has not only improved the pathogenetic understanding of this entity but also increased the diagnostic accuracy of this disorder...
January 2015: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/25332528/plasma-cell-leukaemia-masquerading-as-hairy-cell-leukaemia-a-case-report
#20
Thota Narender Kumar, Kalpathi Krishnamani, Linga Vijay Gandhi, Gundeti Sadashivudu, Digumarti Raghunadharao
Plasma cell leukaemia is a rare and aggressive neoplasm with survival of less than one year with conventional treatment. It can rarely present with morphology mimicking hairy cell leukaemia. We present a case of plasma cell leukaemia with hairy cell morphology for its rarity, diagnostic difficulty and aggressive course.
September 2014: Indian Journal of Hematology & Blood Transfusion
keyword
keyword
33280
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"